Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors

Author:

Liu Fei123,Wang Zixian4,Li Xiaofan5,Zhang Zhen4,Yang Yue5,Chen Junquan4,Chen Dinghua5,Wu Lingling5,Liu Xiangyu6,Han Sujun1,Wang Fangming1,Wahafu Wasilijiang1,Gao Yibo2378,Ren Shancheng9,Xing Nianzeng17,Cai Guangyan5,Chen Xiangmei5

Affiliation:

1. Department of Urology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing P. R. China

2. Laboratory of Translational Medicine National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing P. R. China

3. Department of Thoracic Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing P. R. China

4. Department of Medical Oncology Sun Yat‐sen University Cancer Center Guangzhou Guangdong P. R. China

5. Department of Nephrology First Medical Center of Chinese PLA General Hospital Nephrology Institute of the Chinese People's Liberation Army State Key Laboratory of Kidney Diseases National Clinical Research Center for Kidney Diseases Beijing Key Laboratory of Kidney Disease Research Beijing P. R. China

6. Department of Plastic Surgery Plastic Surgery Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College Beijing PR China

7. State Key Laboratory of Molecular Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing P. R. China

8. Central Laboratory National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Shenzhen Guangdong P. R. China

9. Department of Urology Shanghai Changzheng Hospital Shanghai P. R. China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Oncology

Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3